Pilot Study of a Catheter-based Ultrasound Hyperthermia System (08992)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Ultrasound energy may be able to kill tumor cells by heating up the tumor cells without affecting the surrounding tissue. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving ultrasound hyperthermia therapy after implant radiation therapy may kill more tumor cells.
PURPOSE: This clinical trial is studying ultrasound hyperthermia therapy to see how well it works after implant radiation therapy in treating patients with Stage III/IV cancer of the cervix or prostate cancer with a rising prostate specific antigen (PSA) after prior local therapy.
| Condition | Intervention |
|---|---|
|
Cervical Cancer Prostate Cancer |
Procedure: Hyperthermia Radiation: HDR brachytherapy |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pilot Study of a Catheter-based Ultrasound Hyperthermia System |
- Evaluate the safety and tolerability of interstitial and endocavitary ultrasound hyperthermia therapy [ Time Frame: baseline to completion of study ] [ Designated as safety issue: Yes ]All patients treated with at least one hyperthermia session will be included in the safety analysis. The frequency by grade for all adverse events will be tabulated by type and presented separately for the first and second hyperthermia treatments. In addition, the safety data will be presented for the 2 subsets of patients corresponding to the plan for accrual for gynecological and prostate cancer subgroups: the first 3 patients in each subgroup, then the final 9 patients.
- Evaluate the feasibility, defined as being able to administer hyperthermia at a specified temperature range and thermal dose. [ Time Frame: baseline to completion of study ] [ Designated as safety issue: No ]The feasibility of administering hyperthermia to patients receiving standard brachytherapy will be summarized by the proportion of patients completing the treatment as planned. The proportion and 95% confidence interval will be calculated for each of the two hyperthermia sessions.
- Characterize the interstitial and endocavitary ultrasound heating technology by describing the thermal parameters including attainable temperature and thermal dose distribution and duration at the tumor treatment region. [ Time Frame: baseline to completion of study ] [ Designated as safety issue: No ]Parameters quantifying the therapeutic heat and thermal dose delivered to the tumor treatment regions encountered in the brachytherapy setting will be calculated. Thermal parameters as determined by thermometry measurements will be recorded at each of the two hyperthermia sessions (Tmax, Tmin, T50, T90, CEM (43)T(90). These values will be used to evaluate radial temperature and thermal dose profiles through the clinical target volume for each treatment. Attainable temperature and thermal dose distributions will be summarized using descriptive statistics and presented separately for each hyperthermia treatment and possibly by type of cancer (gynecologic or prostate).
| Estimated Enrollment: | 24 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | May 2018 |
| Estimated Primary Completion Date: | May 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Hyperthermia with HDR brachytherapy
Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
|
Procedure: Hyperthermia
Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
Radiation: HDR brachytherapy
Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
|
Detailed Description:
OUTLINE: Patients undergo standard high-dose rate (HDR) brachytherapy. Approximately 2 hours after brachytherapy, patients undergo catheter-based ultrasound hyperthermia therapy over 60 minutes. Treatment with HDR brachytherapy and hyperthermia therapy repeats within 1-3 weeks. Patients may then undergo 2 additional standard HDR brachytherapy sessions.
After completion of study therapy, patients are followed at 1 and 3 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients who are to be given HDR brachytherapy for treatment of solid tumor of the following:
- Cervical cancer Stage III or IV OR
- Prostate cancer (with rising prostate specific antigen after prior local therapy)
Age ≥18 years
Eligible for brachytherapy as determined per clinical standard of care.
Ability to give written informed consent and willingness to comply with the requirements of the protocol
Exclusion Criteria:
Patients who are not candidates for HDR brachytherapy
Any condition that compromises compliance with the objectives and procedures of this protocol, as judged by the principal investigator
Contacts and Locations| United States, California | |
| UCSF Helen Diller Family Comprehensive Cancer Center | Recruiting |
| San Francisco, California, United States, 94143-1708 | |
| Contact: I-Chow J. Hsu, MD 415-353-7106 ihsu@radonc.ucsf.edu | |
| Contact: Christian J Diederich, PhD 415-476-8641 cdiederich@radonc.ucsf.edu | |
| Sub-Investigator: Christian J Diedrich, PhD | |
| Principal Investigator: | I-Chow J. Hsu, MD | University of California, San Francisco |
More Information
Additional Information:
No publications provided
| Responsible Party: | I-Chow Hsu, Professor, Radiation Oncology, University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT00911079 History of Changes |
| Other Study ID Numbers: | CDR0000643085, 08992, R01CA122276 |
| Study First Received: | May 29, 2009 |
| Last Updated: | November 15, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of California, San Francisco:
|
Stage III, IV cervical cancer Rising prostate specific antigen (PSA) after local therapy |
Additional relevant MeSH terms:
|
Uterine Cervical Neoplasms Fever Prostatic Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms |
Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Body Temperature Changes Signs and Symptoms Genital Neoplasms, Male Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013